Lymphocyte function in wound healing and following injury

British Journal of Surgery

Volumn 85, Issue 4, 1998, Pages 444-460

  Schaffer M ^a,c   Barbul, A ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; CATECHOLAMINE; CD4 ANTIGEN; CD8 ANTIGEN; CYCLIC AMP; CYTOKINE; FIBROBLAST GROWTH FACTOR; GAMMA INTERFERON; GLUCAN; GLUCOCORTICOID; IMMUNOGLOBULIN; INOSINE DERIVATIVE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 6; KETOCONAZOLE; LYMPHOKINE; METHISOPRINOL; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAPEPTIDE; PROSTAGLANDIN E2; RECOMBINANT INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG;

B LYMPHOCYTE; CELLULAR IMMUNITY; COMPLEMENT ACTIVATION; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; IMMUNOMODULATION; LYMPHOCYTE FUNCTION; LYMPHOCYTE SUBPOPULATION; NONHUMAN; NUTRITION; PHAGOCYTE; PRIORITY JOURNAL; RESUSCITATION; REVIEW; T LYMPHOCYTE ACTIVATION; TISSUE INJURY; WOUND HEALING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; B-LYMPHOCYTES; COMPLEMENT SYSTEM PROTEINS; CYTOKINES; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; LYMPHOCYTES; LYMPHOKINES; MICE; NEUTROPHILS; T-LYMPHOCYTES; WOUND HEALING; WOUNDS AND INJURIES;

EID: 0031949259     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2168.1998.00734.x     Document Type: Review

References (226)

1. Feldbush TL, Hobbs MV, Severson CD, Ballas ZK, Weiler JM. Role of complement in the immune response. Fed Proc 1984; 43: 2548-52.
2. Frank MM, Fries LF. The role of complement in inflammation and phagocytosis. Immunol Today 1991; 12: 322-6.
3. Gelfand JA, Donelan M, Burke JF. Preferential activation and depletion of the alternative complement pathway by burn injury. Ann Surg 1983; 198: 58-62.
4. Moore FD Jr, Davis C, Rodrick M, Mannick JA, Fearon DT. Neutrophil activation in thermal injury as assessed by increased expression of complement receptors. N Engl J Med 1986; 314: 948-53.
5. Roumen RM, Redl H, Schlag G, Zilow G, Sandtner W, Koller W et al. Inflammatory mediators in relation to the development of multiple organ failure in patients after severe blunt trauma. Crit Care Med 1995; 23: 474-80.
6. Ezekowitz RAB, Williams DJ, Koziel H, Armstrong MYK, Warner A, Richards FF et al. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature 1991; 351: 155-8.
7. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD 14, a receptor for complexes of lipopolysaccharide (LPS) and LPS-binding protein. Science 1990; 249: 1431-3.
8. Altura BM, Hershey SG. RES phagocyte function in trauma and adaption to experimental shock. Am J Physiol 1968; 215: 1414-19.
9. Loegering DJ. Humoral factor depletion and reticuloendothelial depression during hemorrhagic shock. Am J Physiol 1977; 232: H283-7.
10. Faist E, Mewes A, Strasser T, Walz A, Alkan S, Baker C et al. Alteration of monocyte function following major injury. Arch Surg 1988; 123: 287-92.
11. Ayala A, Ertel W, Chaudry IH. Trauma-induced suppression of antigen presentation and expression of major histocompatibility class II antigen complex in leukocytes. Shock 1996; 5: 79-90 (Editorial).
12. Kelly KJ, Williams WW Jr, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos JC et al. Intercellular adhesion molecule-1-deficient mice are protected against ischemic renal injury. J Clin Invest 1996; 97: 1056-63.
13. Mizgerd JP, Meek BB, Kutkoski GJ, Bullard DC, Beaudet AL, Doerschuk CM. Selectins and neutrophil traffic: margination and Streptococcus pneumoniae-induced emigration in murine lungs. J Exp Med 1996; 184: 639-45.
14. Botha AJ, Moore FA, Moore EE, Peterson VM, Goode AW. Base deficit after major trauma directly relates to neutrophil CD11b expression: a proposed mechanism of shock-induced organ injury. Intensive Care Med 1997; 23: 504-9.
15. Lin RY, Astiz ME, Saxon JC, Rackow EC. Altered leukocyte immunophenotypes in septic shock. Studies of HLA-DR, CD11b, CD14, and IL-2R expression. Chest 1993; 104: 847-53.
16. Engelberts I, van Hoof SCJ, Samyo SK, Buurman WA, van der Linden CJ. Generalized inflammation during peritonitis evidenced by intracutaneous E-selectin expression. Clin Immunol Immunopathol 1992; 65: 330-4.
17. Redl H, Schlag, Hammerschmidt DE. Quantitative assessment of leukostasis in experimental hypovolemictraumatic shock. Acta Chirugica Scandinavica 1984; 150: 113-17.
18. Schlag G, Redl H. Morphology of the microvascular system in shock: lung, liver, and skeletal muscles. Crit Care Med 1985; 13: 1045-9.
19. Bjornson AB, Bjornson HS, Altemeier WA. Serummediated inhibition of polymorphonuclear leucocyte function following burn injury. Ann Surg 1981; 194: 568-75.
20. Grogan JB. Altered neutrophil phagocytic function in burn patients. J Trauma 1976; 16: 734-8.
21. Simms HH, D'Amico R. Polymorphonuclear leukocyte dysregulation during the systemic inflammatory response syndrome. Blood 1994; 83: 1398-407.
22. Malnati MS, Peruzzi M, Parker KC, Biddison WE, Ciccone E, Moretta A et al. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 1995; 267: 1016-18.
23. Lanier LL, Ruitenberg JJ, Phillips JH. Functional and biochemical analysis of CD16 antigen on natural killer cells and granulocytes. J Immunol 1988; 141: 3478-85.
24. Stephan RN, Poo WJ, Janeway CA, Zoghbi SS, Dean RE, Geha AS et al. Prolonged impairment of natural killer cell activity following simple hemorrhage. Circ Shock 1987; 21: 312-13.
25. Pollock RE, Babcock GF, Romsdahl MM, Nishioka K. Surgical stress-mediated suppression of murine natural killer cell cytotoxicity. Cancer Res 1984; 44: 3888-91.
26. Blazer BA, Rodrick ML, O'Mahoney JB, Wood JJ, Bessey PQ, Wilmore DW et al. Suppression of natural killer-cell function in humans following thermal and traumatic injury. J Clin Immunol 1986; 6: 26-36.
27. Martin CW, Muir IFK. The role of lymphocytes in wound healing. Br J Plast Surg 1990; 43: 655-62.
28. Fishel RS, Barbul A, Beschorner WE, Wasserkrug HL, Efron G. Lymphocyte participation in wound healing. Morphologic assessment using monoclonal antibodies. Ann Surg 1987; 206: 25-9.
29. Ross R, Benditt EP. Wound healing and collagen formation. Fine structure in experimental scurvy. J Cell Biol 1962; 12: 533-48.
30. Efron JE, Frankel HL, Lazarou SA, Wasserkrug HL, Barbul A. Wound healing and T-lymphocytes. J Surg Res 1990; 48: 460-3.
31. Barbul A, Breslin RJ, Woodyard JP, Wasserkrug HL, Efron G. The effect of in vivo T helper and T suppressor lymphocyte depletion on wound healing. Ann Surg 1989; 209: 479-83.
32. Barbul A, Shawe T, Rotter SM, Efron J, Wasserkrug HL, Badawy SB. Wound healing in nude mice: a study on the regulatory role of lymphocytes in fibroplasia. Surgery 1989; 105: 764-9.
33. Barbul A, Shawe T, Frankel HL, Efron JE, Wasserkrug HL. Inhibition of wound repair by thymic hormones. Surgery 1989; 106: 373-6.
34. Prudden JF, Nishihara G, Ocampo I. Studies on growth hormone: III. The effect on wound tensile strength of marked postoperative anabolism induced with growth hormone. Surg Gynecol Obstet 1958; 107: 481-2.
35. Ehrlich HP, Hunt TK. The effects of cortisone and anabolic steroids on the tensile strength of healing wounds. Ann Surg 1969; 170: 203-6.
36. Kirk SJ, Hurson M, Regan MC, Holt DR, Wasserkrug HL, Barbul A. Arginine stimulates wound healing and immune function in elderly human beings. Surgery 1993; 114: 155-60.
37. Fishel R, Barbul A, Wasserkrug HL, Penberthy LT, Rettura G, Efron G. Cyclosporin A impairs wound healing in rats. J Surg Res 1983; 34: 572-5.
38. Schäffer M, Fuchs N, Prok̇sch B, Bongartz M, Beiter T, Völker J et al. Tacrolimus impairs wound healing: role of nitric oxide synthesis. In: Faist E, ed. The Immune Consequences of Trauma, Shock and Sepsis. Bologna: Monduzzi, 1997: 87-90.
39. Schäffer MR, Tantry U, Gross SS, Wasserkrug HL, Barbul A. Nitric oxide regulates wound healing. J Surg Res 1996; 63: 237-40.
40. Barbul A, Sisto D, Rettura G. Levenson SM, Seifter E, Efron G. Thymic inhibition of wound healing: abrogation by adult thymectomy. J Surg Res 1982; 32: 338-42.
41. Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH. Stimulation of the chemotactic migration of human fibroblasts by transforming growth factorβ. J Exp Med 1987; 165: 251-6.
42. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM et al. Transforming growth factor type β: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 1986; 83: 4167-71.
43. Thornton SC, Por SB, Walsh BJ, Penney R, Breit SN. Interaction of immune and connective tissue cells: I. The effect of lymphokines and monokines on fibroblast growth. J Leukoc Biol 1990; 47: 312-20.
44. Nielson EG, Phillips SM, Jimenez S. Lymphokine modulation of fibroblast proliferation. J Immunol 1982; 128: 1484-6.
45. Duncan MR, Berman B. γ-Interferon is the lymphokine and β-interferon the monokine responsible for inhibition of fibroblast collagen production and late not early fibroblast proliferation. J Exp Med 1985; 162: 516-27.
46. Solis-Herruzo JA, Brenner DA, Chojkier M. Tumor necrosis factor α inhibits collagen gene transcription and collagen synthesis in cultured human fibroblasts. J Biol Chem 1988; 263: 5841-5.
47. Wahl SM. Host immune factors regulating fibrosis. In: Fibrosis. Ciba Foundation Symposium 114. London: Pitman, 1985: 175-95.
48. Ford HR, Hoffmann RA, Wing EJ, Magee DM, Mclntyre L, Simmons RL. Characterization of wound cytokines in the sponge matrix model. Arch Surg 1989; 124: 1422-8.
49. Cromack DT, Sporn MB, Roberts AB, Merino MJ, Dart LL, Norton JA. Transforming growth factor β levels in ral wound chambers. J Surg Res 1987; 42: 622-8.
50. Mustoe TA, Pierce GF, Thomason A, Gramates P, Sporn MB, Deuel TF. Accelerated healing of incisional wounds in rats induced by transforming growth factor-β. Science 1987; 237: 1333-6.
51. 1. Wound Rep Reg 1995; 3: 330-9.
52. Shah M, Foreman DM, Ferguson MWJ. Neutralising antibody to TGF-beta 1, 2 reduces cutaneous scarring in adult rodents. J Cell Sci 1994; 107: 1137-57.
53. Barbul A, Knud-Hansen J, Wasserkrug HL, Efron G. Interleukin 2 enhances wound healing in rats. J Surg Res 1986; 40: 315-19.
54. Breslin RJ, Barbul A, Kupper TS, Knud-Hansen JP, Wasserkrug HL, Efron G. Generation of an anti-interleukin 2 factor in healing wounds. Arch Surg 1988; 123: 305-8.
55. Granstein RD, Murphy GF, Margolis RJ, Byrne MH, Amento EP. Gamma-interteron inhibits collagen synthesis in vivo in the mouse. J Clin Invest 1987; 79: 1254-8.
56. Regan MC, Kirk SJ, Hurson M, Sodeyama M, Wasserkrug HL, Barbul A. Tumor necrosis factor-α inhibits in vivo collagen synthesis. Surgery 1993; 113: 173-7.
57. Salomon GD, Kasid A, Cromack DT, Director E, Talbot TL, Sank A et al. The local effect of cachectin/tumor necrosis factor on wound healing. Ann Surg 1991; 214: 175-80.
58. Castagnoli C, Stella M, Berthod C, Magliacani G, Richiardi PM. TNF production and hypertrophie scarring. Cell Immunol 1993; 147: 51-63.
59. Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). Ann Surg 1986; 204: 322-30.
60. Brown GL, Nanney LB, Griffen J, Cramer AB, Yancey JM, Curtsinger LJ III. Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 1989; 321: 76-9.
61. Knighton DR, Ciresi K, Fiegel VD, Schumerth S, Butler E, Cerra F. Stimulation of repair in chronic, nonhealing, cutaneous ulcers using platelet-derived wound healing formula. Surg Gynecol Obstet 1990; 170: 56-60.
62. Robson MC, Phillips LG, Thomason A, Altrock BW, Pence PC, Heggers JP et al. Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers. Ann Plast Surg 1992; 29: 193-201.
63. Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vase Surg 1992; 16: 251-7.
64. Richard J-L, Parer-Richard C, Daures J-P, Clouet S, Vannereau D, Bringer J et al. Effect of topical basic fibroblast growth factor on the healing of chronic diabetic neuropathic ulcer of the foot. A pilot, randomized, doubleblind, placebo-controlled study. Diabetes Care 1995; 18: 64-9.
65. Robson MC, Abdulla A, Burns BF, Phillips LG, Garrison L, Gowan W et al. Safety and effect of topical recombinant human interleukin-1β in the management of pressure sores. Wound Rep Reg 1994; 2: 177-81.
66. Robson MC. The role of growth factors in the healing of chronic wounds. Wound Rep Reg 1997; 5: 12-17.
67. Crary B, Borysenko M, Sutherland DC, Kutz I, Borysenko JZ, Benson H. Decrease in mitogen responsiveness of mononuclear cells from peripheral blood after epinephrine administration in humans. J Immunol 1983; 130: 694-7.
68. Feldman RD, Hunninghake GW, McArdle WL. Beta-adrenerg-receptor-mediated suppression of interleukin 2 receptors in human lymphocytes. J Immunol 1987; 139: 3355-9.
69. Loegering DJ, Commins LM. Effect of beta-receptor stimulation on Kupffer cell complement receptor clearance function. Circ Shock 1988; 25: 325-32.
70. Fuenfer MM, Olson GE, Polk HC Jr. Effect of various corticosteroids upon the phagocytic bactericidal activity of neutrophils. Surgery 1975; 78: 27-33.
71. Hawes AS, Richardson RP, Antonacci AC, Calvano SE. Chronic pathophysiologic elevation of corticosterone after thermal injury or thermal injury and burn wound infection adversely affects body mass, lymphocyte numbers, and outcome. J Burn Care Rehabil 1995; 16: 1-15.
72. Snyder DS, Unanue ER. Corticosteroids inhibit murine macrophage la expression and interleukin 1 production. J Immunol 1982; 129: 1803-5.
73. Bolton PM, Kirov SM, Donald KJ. The effect of major and minor trauma on lymphocyte kinetics in mice. Aust J Exp Biol Med Sci 1979; 57: 479-92.
74. Slade MS, Simmons RL, Yunis E, Greenberg LJ. Immunodepression after major surgery in normal patients. Surgery 1975; 78: 363-72.
75. Ninnemann JL, Fisher JC, Frank HA. Prolonged survival of human skin allografts following thermal injury. Transplantation 1978; 25: 69-72.
76. Lewis MR, Cole WH. Experimental increase of lung metastases after operative trauma (amputation of limb with tumor). Arch Surg 1958; 77: 621-6.
77. Constantian MB. Association of sepsis with an immunosuppressive polypeptide in the serum of burn patients. Ann Surg 1978; 188: 209-15.
78. Ninnemann JL, Fisher JC, Wachtel TL. Thermal injuryassociated immunosuppression; occurrence and in vitro blocking effect of the post recovery serum. J Immunol 1979; 122: 1736-41.
79. O'Mahony JB, Palder SB, Wood JJ, Mclrvine A, Rodrick ML, Demling RH et al. Depression of cellular immunity after multiple trauma in the absence of sepsis. J Trauma 1984; 24: 869-75.
80. Barbul A, Fishel RS, Shimazu S, Damewood RB, Wasserkrug HL, Efron G. Inhibition of host immunity by fluid and mononuclear cells from healing wounds. Surgery 1984; 96: 315-20.
81. Lazarou SA, Barbul A, Wasserkrug HL, Efron G. The wound is a possible source of posttraumatic immunosuppression. Arch Surg 1989; 124: 1429-31.
82. 2 in immune suppression following injury. Ann Surg 1991; 214: 253-63.
83. 2)-dependent suppression of interleukin alpha (IL-2) production in patients with major trauma. J Trauma 1987; 27: 837-48.
84. 2 regulates macrophage-derived tumor necrosis factor gene expression. J Biol Chern 1988; 263: 5380-4.
85. Horgan AF, O'Riordain DS, Chin DHL, Mannick JA, Rodrick ML. The role of cyclic adenosine monophosphate in the suppression of cellular immunity after thermal injury. Arch Surg 1994; 129: 1284-9.
86. 2-induced T-lymphocyte proliferative suppression in sepsis. Infect Immun 1995; 63: 3101-5.
87. Sayeed MM. Alterations in calcium signaling and cellular responses in septic injury. New Horiz 1996; 4: 72-86.
88. Faist E, Schinkel C, Zimmer S. Update on the mechanisms of immune suppression of injury and immune modulation. World J Surg 1996; 20: 454-9.
89. Ninnemann JL, Ozkan AN, Sullivan JJ. Hemolysis and suppression of neutrophil chemotaxis by a low molecular weight component of human burn patient sera. Immunol Lett 1985; 10: 63-9.
90. Biffl WL, Moore EE, Moore FA, Peterson VM. Interleukin-6 in the injured patient. Marker of injury or mediator of inflammation? Ann Surg 1996; 224: 647-64.
91. van der Poll T, Lowry SF. Tumor necrosis factor in sepsis: mediator of multiple organ failure or essential part of host defense? Shock 1995; 3: 1-12 (Editorial).
92. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996; 24: 163-72.
93. Ahmad S, Choudhry MA, Shankar R, Sayeed MM. Transforming growth factor-beta negatively modulates T-cell responses in sepsis. FEBS Lett 1997; 402: 213-18.
94. Meert KL, Ofenstein JP, Genyea C, Sarnaik AP, Kaplan J. Elevated transforming growth factor-beta concentration correlates with posttrauma immunosuppression. J Trauma 1996; 40: 901-6.
95. Klava A, Windsor AC, Farmery SM, Woodhouse LF, Reynolds JV, Ramsden CW et al. Interleukin-10. A role in the development of postoperative immunosuppression. Arch Surg 1997; 132: 425-9.
96. Napolitano LM, Campbell C. Polymicrobial sepsis following trauma inhibits interleukin-10 secretion and lymphocyte proliferation. J Trauma 1995; 39: 104-10.
97. Standiford TJ, Stricter RM, Lukacs NW, Kunkel SL. Neutralization of IL-I0 increases lethality in endotoxemia. Cooperative effects of macrophage inflammatory protein-2 and tumor necrosis factor. J Immunol 1995; 155: 2222-9.
98. van der Poll T, Marchant A, Berman L, Lazarus DD, Keogh CV, Nguyen L et al. Endogenous interleukin-10 protects against death in septic peritonitis in mice. Surg Forum 1994; 45: 18-20.
99. Greenberger MJ, Stricter RM, Kunkel SL, Danforth JM, Goodman RE, Standiford TJ. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol 1995; 155: 722-9.
100. Hauser CJ, Joshi P, Zhou X, Kregor P, Hardy KJ, Devidas M et al. Production of interleukin-10 in human fracture soft-tissue hematomas. Shock 1996; 6: 3-6.
101. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A 1992; 89: 4845-9.
102. Giri JG, Newton RC, Horuk R. Identification of soluble interleukin-1 binding protein in cell-free supernatants. Evidence for soluble interleukin-1 receptor. J Biol Chem 1990; 265: 17 416-19.
103. Nophar Y, Kemper O, Brakebusch H, Englemann H, Zwang R, Aderka D et al. Soluble forms of tumor necrosis factor receptors (TNF-Rs): the cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 1990; 39: 3269-78.
104. Hultman CS, Cairns BA, deSerres S, Frelinger JA, Meyer AA. Early, complete burn wound excision partially restores cytotoxic T lymphocyte function. Surgery 1995; 118: 421-9.
105. Moss NM, Gough DB, Jordan AL, Grbic JT, Wood JJ, Rodrick ML et al. Temporal correlation of impaired immune response after thermal injury with susceptibility to infection in a murine model. Surgery 1988; 104: 882-7.
106. Branch CD, Wilkins GF, Ross FP. The coagulum contact method (SANO) of skin grafting in the treatment of burns and wounds. Surgery 1946; 19: 460-6.
107. Faist E, Schinkel C, Zimmer S, Kremer JP, von Donnersmarck GH, Schildberg FW. Inadequate interleukin-2 synthesis and interleukin-2 messenger expression following thermal and mechanical trauma in humans is caused by defective transmembrane signalling. J Trauma 1993; 34: 846-54.
108. Meldrum DR, Ayala A, Perrin MM, Ertel W, Chaudry IH. Diltiazem restores IL-2, IL-3, IL-6, and IFN-γ synthesis and decreases host susceptibility to sepsis following hemorrhage. J Surg Res 1991; 51: 158-64.
109. O'Riordain DS, Mendez MV, O'Riordain MG. Molloy RG, Holzheimer RG, Collins K et al. Molecular mechanisms of decreased interleukin-2 production after thermal injury. Surgery 1993; 114: 407-15.
110. Horgan AF, Mendez MV, O'Riordain DS, Holzheimer RG, Mannick JA, Rodrick ML. Altered gene transcription after burn injury results in depressed T-lymphocyte activation. Ann Surg 1994; 220: 342-52.
111. Stephan RN, Kupper TS, Geha AS, Baue AS, Chaudry IH. Hemorrhage without tissue trauma produces immunosuppression and enhances susceptibility to sepsis. Arch Surg 1987; 122: 62-8.
112. Keane RM, Birmingham W, Shatney CM, Winchurch RA, Munster AM. Prediction of sepsis in the multitraumatic patient by lymphocyte responsiveness. Surg Gynecol Obstet 1983; 156: 163-7.
113. Janeway CA Jr. The T cell receptor as a multicomponent signaling machine: CD4/CD8 coreceptors and CD45 in T cell activation. Annu Rev Immunol 1992; 10: 645-74.
114. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994; 76: 263-74.
115. Organ BC, Antonacci AC, Chiao J, Chiao J, Kumar A, de Riesthal HF et al. Changes in lymphocyte number and phenotype in seven lymphoid compartments after thermal injury. Ann Surg 1989; 210: 78-89.
116. Zapata-Sirvent RL, Hansbrough JF. Temporal analysis of human leucocyte surface antigen expression and neutrophil respiratory burst activity after thermal injury. Burns 1993; 19: 5-11.
117. Kupper TS, Baker CC, Ferguson TA, Green DR. A burn induced Ly-2 suppressor T cell lowers resistance to bacterial infection. J Surg Res 1985; 38: 606-12.
118. Burleson DG, Mason AD Jr, Pruitt BA Jr. Lymphoid subpopulation changes after thermal injury and thermal injury with infection in an experimental model. Arch Surg 1988; 207: 208-12.
119. O'Mahony JB, Wood JJ, Rodrick ML, Mannick JA. Changes in T lymphocyte subsets following injury. Assessment by flow cytometry and relationship to sepsis. Ann Surg 1985; 202: 580-6.
120. Abraham E, Freitas AA. Hemorrhage produces abnormalities in lymphocyte function and lymphokine generation. J Immunol 1989; 142: 899-906.
121. Feeney C, Bryzman S, Kong L, Brazil H, Deutsch R, Fritz LC. T-lymphocyte subsets in acute illness. Crit Care Med 1995; 23: 1680-5.
122. Decker D, Schondorf M, Bidlingmaier F, Hirner A, von Ruecker AA. Surgical stress induces a shift in the type 1/type 2 T-helper cell balance, suggesting down-regulation of cell-mediated and up-regulation of antibody-mediated immunity commensurate to the trauma. Surgery 1996; 119: 316-25.
123. Mack VE, McCarter MD, Naama HA, Calvano SE, Daly JM. Dominance of T-helper 2-type cytokines after severe injury. Arch Surg 1996; 131: 1303-9.
124. O'Sullivan ST, Lederer JA, Horgan AF, Chin DH, Mannick JA, Rodrick ML. Major injury leads to predominance of the T helper 2-lymphocyte phenotype and diminished interleukin-12 production associated with decreased resistance to infection. Ann Surg 1995; 222: 482-90.
125. O'Suilleabhain C, O'Sullivan ST, Kelly JL, Lederer J, Mannick JA, Rodrick ML. Interleukin-12 treatment restores normal resistance to bacterial challenge after burn injury. Surgery 1996; 120: 290-6.
126. Wood JJ, O'Mahony JB, Rodrick ML, Mannick JA. Immature T lymphocytes after injury characterized by morphology and phenotypic markers. Ann Surg 1987; 206: 564-71.
127. Dong Y, Yan T, Herndon DN, Waymack JP. Alterations in intracellular lymphocyte metabolism induced by infection and injury. J Surg Res 1992; 53: 293-7.
128. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993; 11: 245-68.
129. Goronzy J, Weyand C, Quan J, Fathman CG, O'Hanley P. Enhanced cell-mediated protection against fatal Escherichia coil septicemia induced by treatment with recombinant IL-2. J Immunol 1989; 142: 1134-8.
130. Wood JJ, O'Mahony JB, Rodrick ML, Eaton R, Demling RH, Mannick JA. Abnormalities of antibody production after thermal injury. An association with reduced interleukin 2 production. Arch Surg 1986; 121: 108-15.
131. Teodorczyk-Injeyan JA, McRitchie DI, Peters WJ, Lalani S, Girotti MJ. Expression and secretion of IL-2 receptor in trauma patients. Ann Surg 1990; 212: 202-8.
132. Sayeed MM. Alterations in cell signaling and related effector functions in T-lymphocytes in burn/trauma/septic injuries. Shock 1996; 5: 157-66 (Editorial).
133. Schluter B, König W, Koller M, Erbs G, Müller FE. Differential regulation of T- and B-lymphocyte activation in severely burned patients. J Trauma 1991; 31: 239-46.
134. O'Riordain DS, Mendez MV, Holzheimer RG, Collins K, Mannick JA, Rodrick ML. Interleukin-2 receptor expression and function following thermal injury. Arch Surg 1995; 130: 165-70.
135. Abraham E, Freitas AA. Hemorrhage in mice induces alterations in immunoglobulin-secreting B cells. Crit Care Med 1989; 17: 1015-19.
136. Ayala A, Ertel W, Chaudry IH. Trauma-induced suppression of antigen presentation and expression of major histocompatibility class II antigen complex in leukocytes. Shock 1996; 5: 79-90 (Editorial).
137. Albina JE, Henry WL Jr. Suppression of lymphocyte proliferation through the nitric oxide synthesizing pathway. J Surg Res 1991; 50: 403-9.
138. Napolitano LM, Campbell C. Nitric oxide inhibition normalizes splenocyte interleukin-10 synthesis in murine thermal injury. Arch Surg 1994; 129: 1276-82.
139. Taylor-Robinson AW, Liew FY, Severn A, Xu D, McSorley SJ, Garside P et al. Regulation of the immune response by nitric oxide differentially produced by T helper type 1 and T helper type 2 cells. Eur J Immunol 1994; 24: 980-4.
140. Wei XO, Charles IG, Smith A, Ure J, Feng GJ, Huang FP et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 1995; 375: 408-11.
141. Ianaro A, O'Donnell CA, Di Rosa M, Liew FY. A nitric oxide synthase inhibitor reduces inflammation, down-regulates inflammatory cytokines and enhances interleukin-10 production in carrageenin-induced oedema in mice Immunology 1994; 82: 370-5.
142. Efron DT, Kirk SJ, Regan MC, Wasserkrug HL, Barbul A. Nitric oxide generation from L-arginine is required for optimal human peripheral blood lymphocyte DNA synthesis. Surgery 1991; 110: 327-34.
143. Kolpakov V, Gordon D, Kulik J. Nitric oxide-generating compounds inhibit total protein and collagen synthesis in cultured vascular smooth muscle cells. Circ Res 1995; 76: 305-9.
144. Schäffer M, Efron PA, Thornton FJ, Klingel K, Gross SS, Barbul A. Nitric oxide, an autokrine regulator of wound fibroblast synthetic function. J Immunol 1997; 158: 2375-81.
145. Parker DC. T cell-dependent B-cell activation. Annu Rev Immunol 1993; 11: 331-60.
146. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. A 39-kDa protein in activated helper T cells hinds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A 1992; 89: 6550-4.
147. Harriman W, Volk H, Defranoux N, Wabl M. Immunoglobulin class switch recombination. Annu Rev Immunol 1993; 11: 361-84.
148. Pecanha LM, Snapper CM, Finkelman FD, Mond JJ. Dextran-conjugated anti-Ig antibodies as a model for T-cell-independent type 2 antigen-mediated stimulation of Ig secretion in vitro. Lymphokine dependence. J Immunol 1991; 146: 833-9.
149. Ertel W, Faist E, Nestle C, Schuebel I, Storck M, Schildberg FW. Dynamics of immunoglobulin synthesis after major trauma. Influence of recombinant lymphokines. Arch Surg 1989; 124: 1437-42.
150. McRitchie DA, Girotti MJ, Rotstein OD, Teodorczyk-Injeyan JA, Impaired antibody production in blunt trauma. Possible role for T cell dysfunction. Arch Surg 1990; 125: 91-6.
151. Wilson NW, Ochs HD, Peterson B, Hamburger RN, Bastian JF. Abnormal primary antibody responses in pediatric trauma patients. J Pediatr 1989; 115: 424-7.
152. Slade MS, Simmons RL, Yunis E, Greenberg LJ. Immunodepression after major surgery in normal patients. Surgery 1975; 78: 363-72.
153. Munster AM, Hoagland HC, Pruitt BA Jr. The effect of thermal injury on serum immunoglobulins. Ann Surg 1970; 172: 965-9.
154. Casey J, Flinn WR, Yao JS, Fahey V, Pawlowski J, Bergan JJ. Correlation of immune and nutritional status with wound complications in patients undergoing vascular operations. Surgery 1983; 93: 822-7.
155. Alexander JW, MacMillan BG, Stinnett JD, Ogle CK, Bozian RC, Fischer JE et al. Beneficial effects of aggressive protein feeding in severely burned children. Ann Surg 1980; 192: 505-17.
156. Kudsk KA, Croce MA, Fabian TC, Minard G, Tolley EA, Poret HA et al. Enteral versus parenteral feeding. Effects on septic morbidity after blunt and penetrating abdominal trauma. Ann Surg 1992; 215: 503-13.
157. Moore FA, Feliciano DV, Andrassy RJ, McArdle AH, Booth FV, Morgenstein-Wagner TB et al. Early enteral feeding, compared with parenteral, reduces postoperative septic complications. The results of a meta-analysis. Ann Surg 1992; 216: 172-83.
158. Bower RH, Cerra FB, Bershadsky B, Licari JJ, Hoyt DB, Jensen GL et al. Early enterai administration of a formula (Impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit Care Med 1995; 23: 436-49.
159. Braga M, Vignali A, Gianotti L, Cestari A, Profili M, Di Carlo V. Immune and nutritional effects of early enteral nutrition after major abdominal operations. Eur J Surg 1996; 162: 105-12.
160. Chiarelli A, Enzi G, Casadei A, Baggio B, Valerio A, Mazzoleni F. Very early nutrition supplementation in burned patients. Am J Clin Nutr 1990; 51: 1035-9.
161. Duly JM, Lieberman MD, Goldfine J, Shou J, Weintraub F, Rosato EF et al. Enteral nutrition with supplemental arginine, RNA, and omega-3 fatty acids in patients after operation: immunologic, metabolic, and clinical outcome. Surgery 1992; 112: 56-67.
162. Braga M, Gianotti L, Cestari A, Vignali A, Pellegatta F, Dolci A et al. Gut function and immune and inflammatory responses in patients perioperatively fed with supplemented enteral formulas. Arch Surg 1996; 131: 1257-65.
163. Saito H, Trocki O, Wang SL, Gonce SJ, Joffe SJ, Alexander JW. Metabolic and immune effects of dietary arginine supplementation after burn. Arch Surg 1987; 122: 784-9.
164. Gonce SJ, Peck MD, Alexander JW, Miskell PW. Arginine supplementation and its effects on established peritonitis in guinea pigs. JPEN J Parenter Enterai Nutr 1990; 14: 237-44.
165. Seifter E, Rettura G, Barbul A, Levenson SM. Arginine: an essential amino acid for injured rats. Surgery 1978; 84: 224-30.
166. Barbul A, Lazarou SA, Efron DT, Wasserkrug HL, Efron G. Arginine enhances wound healing and lymphocyte immune responses in humans. Surgery 1990; 108: 331-7.
167. Daley JM, Reynolds J, Thom A, Kinsley L, Dietrick-Gallagher M, Shou J et al. Immune and metabolic effects of arginine in the surgical patient. Ann Surg 1988; 208: 512-22.
168. Souba WW, Klimberg VS, Plumley DA, Salloum RM, Flynn TC, Bland KI et al. The role of glutamine in maintaining a healthy gut and supporting the metabolic response to injury and infection. J Surg Res 1990; 48: 383-91.
169. Askanazi J, Carpentier YA, Michelson CB, Elwyn DH, Furst P, Kantrowitz LR et al. Muscle and plasma amino acids following injury. Influence of intercurrent infection. Ann Surg 1980; 192: 78-85.
170. Roth E, Funovics J, Mühlbacher F, Schemper M, Mauritz W, Sporn P et al. Metabolic disorders in severe abdominal sepsis: glutamine deficiency in skeletal muscle. Clin Nutr 1982; 1: 25-41.
171. Stehle P, Zander J, Mertes N, Albers S, Puchstein C, Lawin P et al. Effect of parenteral glutamine peptide supplements on muscle glutamine loss and nitrogen balance after major surgery. Lancet 1989; i: 231-3.
172. Ziegler TR, Young LS, Benfell K, Scheltinga M, Hortos K, Bye R et al. Clinical and metabolic efficacy of glutamine-supplemented parenteral nutrition after bone marrow transplantation. A randomized, double-blind, controlled study. Ann Intern Med 1992; 116: 821-8.
173. Ayala A, Chaudry IH. Dietary n-3 polyunsaturated fatty acid modulation of immune cell function before or after trauma. Nutrition 1995; 11: 1-11.
174. Fanslow WC, Kulkarni AD, Van Buren CT, Rudolph FB. Effect of nucleotide restriction and supplementation on resistance to experimental murine candidiasis. JPEN J Parenter Enterai Nutr 1988; 12: 49-52.
175. Rudolph FB, Kulkarni AD, Schandle VB, Van Buren CT. Involvement of dietary nucleotides in T lymphocyte function. Adv Exp Med Biol 1984; 165B: 175-8.
176. Alexander JW, Gottschlich MM. Nutritional immunomodulation in burn patients. Crit Care Med 1990; 18 (Suppl 2): S149-53.
177. Gottschlich MM, Jenkins M, Warden GD, Baumer T, Havens P, Snook JT et al. Differential effects of three enteral dietary regimens on selected outcome variables in burn patients. JPEN J Parenter Enterai Nutr 1990; 14: 225-36.
178. Moore FA, Moore EE, Kudsk KA, Brown RO, Bower RH, Koruda MJ et al. Clinical benefits of an immune-enhancing diet for early postinjury enterai feeding. J Trauma 1994; 37: 607-15.
179. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicentre clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273: 934-41.
180. Fisher CJ Jr, Opal SM, Dhainaut JF, Stephens S, Zimmerman JL, Nightingale P et al. Influence of an antitumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21: 318-27.
181. Fischer CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC et al.
182. Fisher CJ Jr, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo controlled multicenter trial. The IL-1RA Sepsis Syndrome Study Group. Crit Care Med 1994; 22: 12-21.
183. Fisher CJ Jr, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-43.
184. Cioffi WG Jr, Burleson DG, Jordan BS, Becker WK, McManus WF, Mason AD Jr et al. Effects of granulocyte-macrophage colony-stimulating factor in burn patients. Arch Surg 1991; 126: 74-9.
185. Hartung T, Docke WD, Gantner F, Krieger G, Sauer A, Stevens P et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995; 85: 2482-9.
186. Weyand C, Goronzy J, Fathman CG, O'Hanley P. Administration in vivo of recombinant interleukin 2 protects mice against septic death. J Clin Invest 1987; 79: 1756-63.
187. Livingston DH, Malangoni MA. Interferon-gamma restores immune competence after hemorrhagic shock. J Surg Res 1988; 45: 37-43.
188. Hershman MJ, Appel SH, Wellhausen SR, Sonnenfeld G, Polk HC Jr. Interferon-gamma treatment increases HLA-DR expression on monocytes in severely injured patients. Clin Exp Immunol 1989; 77: 67-70.
189. Polk HC Jr, Cheadle WG, Livingston DH, Rodriguez JL, Starko KM, Izu AE et al. A randomized prospective clinical trial to determine the efficacy of interferon-gamma in severely injured patients. Am J Surg 1992; 163: 191-6.
190. Ertel W, Morrison MH, Ayala A, Perrin MM, Chaudry IH. Blockade of prostaglandin production increases cachectin synthesis and prevents depression of macrophage functions after hemorrhagic shock. Ann Surg 1991; 213: 265-71.
191. Ertel W, Morrison MH, Meldrum DR, Ayala A, Chaudry IH. Ibuprofen restores cellular immunity and decreases susceptibility to sepsis following hemorrhage. J Surg Res 1992; 53: 55-61.
192. Dong YL, Fleming RY, Yan TZ, Herndon DN, Waymack CP. Effect of ibuprofen on the inflammatory response to surgical wounds. J Trauma 1993; 35: 340-3.
193. Hubbard JD, Janssen HF. Increased microvascular permeability in canine endotoxic shock: protective effects of ibuprofen. Circ Shock 1988; 26: 169-83.
194. Waymack JP. The effect of ibuprofen on postburn metabolic and immunologic function. J Surg Res 1989; 46: 172-6.
195. Faist E, Ertel W, Cohnert T, Huber P, Inthorn D, Heberer G. Immnunoprotective effects of cyclooxygenase inhibition in patients with major surgical trauma. J Trauma 1990; 30: 8-18.
196. Faist E, Markewitz A, Fuchs D, Lang S, Zarius S, Schildberg FW et al. Immunomodulatory therapy with thymopentin and indomethacin. Successful restoration of interleukin-2 synthesis in patients undergoing major surgery. Ann Surg 1991; 214: 264-75.
197. Gogos CA, Maroulis J, Zoumbos NC, Salsa B, Kalfarentzos F. The effect of parenteral indomethacin on T-lymphocyte subpopulations and cytokine production in patients under major surgical operations. Res Exp Meet (Berl) 1995; 195: 85-92.
198. 2 formation is increased in human sepsis syndrome. Effects of cyciooxygenase inhibition. Am Rev Respir Dis 1991; 144: 1095-101.
199. Hadden JW, Hadden EM. Therapy of secondary T-cell immunodeficiencies with biological substances and drugs: an update. In: Faist E, Meakins J, Schildberg FW, eds. Host Defense Dysfunction in Trauma, Shock and Sepsis. Berlin: Springer, 1993: 1097-107.
200. 1 on interleukin-2 production and interleukin-2 receptor expression in normal human lymphocytes. Int J Immunopharmacol 1989; 11: 789-800.
201. Singh H, Herndon DN. Effect of isoprinosine on lymphocyte proliferation and natural killer cell activity following thermal injury. Immunopharmacol Immunotoxicol 1989; 11: 631-44.
202. Faist E, Ertel W, Salmen B, Weiler A, Ressel C, Bolla K et al. The immune-enhancing effect of perioperative thymopentin administration in elderly patients undergoing major surgery. Arch Surg 1988; 123: 1449-53.
203. Faist E, Markewitz A, Enfres S, Fuchs D, Hültner L, Lang S. Progress in antiinfective perioperative immunomodulatory therapy with simultaneous administration of blocking and enhancing agents. In: Faist E, Meakins J, Schildherg FW, eds. Host Defense Dysfunction in Trauma, Shock and Sepsis. Berlin: Springer, 1993: 1109-29.
204. Stinnett JD, Loose LD, Miskell P, Tenney CL, Gonce SJ, Alexander JW. Synthetic immunomodulators for prevention of fatal infections in a burned guinea pig model. Ann Surg 1983; 198: 53-7.
205. Waymack JP, Miskell P, Gonce SJ, Alexander JW. Immunomodulators in the treatment of peritonitis in burned and malnourished animals. Surgery 1984; 96: 308-14.
206. Waymack JP, Jenkins M, Warden GD, Solomkin J, Law E Jr, Hummel R et al. A prospective study of thymopentin in severely burned patients. Surg Gynecol Obstet 1987; 164: 423-30.
207. Dalhoff A. Synergy between acylureidopenicillins and immunoglobulin G in experimental animals. Am J Med 1984; 76: 91-100.
208. Class I, Schorer R. Adjuvant therapy with Pseudomonas immunoglobulin in artificially ventilated patients at a surgical intensive care unit. Anasthesie, Intensivtherapie, Notfallmedizin 1989; 24: 167-71.
209. Dominioni L, Dionigi R, Zanello M, Chiaranda M, Acquarolo A, Ballabio A et al. Effects of high-dose IgG on survival of surgical patients with sepsis scores of 20 or greater. Arch Surg 1991; 126: 236-40.
210. Glinz W, Grob PJ, Nydegger UE, Ricklin T, Stamm F, Stoffel D et al. Polyvalent immunoglobulins for prophylaxis of bacterial infections in patients following multiple trauma. A randomized, placebo-controlled study. Intensive Care Med 1985; 11: 288-94.
211. Greenman RL, Schein RMH, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991; 266: 1097-102.
212. Jesdinsky HJ, Tempel G, Castrup HJ, Seifert J. Cooperative Group of Additional Immunoglobulin Therapy in Severe Bacterial Infections: results of a multicenter randomized controlled trial in cases of diffuse fibrinopurulent peritonitis. Klin Wochenschr 1987; 65: 1132-8.
213. Lehmkuhl P, Pichelmayr I. Sepsis-Therapie mit 5-S-Immunglobulinen. In: Deutsch E, Gadner H, Graninger W, Kleinberger G, Lenz K, Ritz R et al., eds. Infektionen auf Intensivstationen. Vienna: Springer, 1991: 127-37.
214. McCloskey RV, Straube RC, Sanders C, Smith SM, Smith CR. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebocontrolled trial. Ann Intern Med 1994; 121: 1-5.
215. Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324: 429-36.
216. Babineau TJ, Hackford A, Kenler A, Bistrian B, Forse RA, Fairchild PG et al. A phase II multicenter, double-blind, randomized, placebo-controlled study of three dosages of an immunomodulator (PGG-glucan) in high-risk surgical patients. Arch Surg 1994; 129: 1204-10.
217. Yu M, Tomasa G, A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 1994; 21: 1635-42.
218. Fourrier F, Chopin C, Huart JJ, Runge I, Caron C, Goudemand J. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation. Chest 1993; 104: 882-8.
219. Robertson FM, Offner PJ, Ciceri DP, Becker WK, Pruitt BA Jr. Detrimental hemodynamic effects of nitric oxide synthase inhibition in septic shock. Arch Surg 1994; 129: 149-55.
220. Wright CE, Rees DD, Moncada S. Protective and pathological roles of nitric oxide in endotoxin shock. Cardiovasc Res 1992; 26: 48-57.
221. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc Res 1994; 28: 34-9.
222. Harbrecht BG, Billiar TR, Stadler J, Demetris AJ, Ochoa J, Curran RD et al. Nitric oxide serves to reduce hepatic damage during murine endotoxemia. Crit Care Med 1992; 20: 1568-74.
223. Boughton-Smith NK, Hutcheson IR, Deakin AM, Whittle BJ, Moncada S. Protective effect of S-nitroso-N-acetyl-penicillamine in endotoxine-induced acute intestinal damage in the rat. Eur J Pharmacol 1990; 191: 485-8.
224. Mizutani T, Layon AJ. Clinical applications of nitric oxide. Chest 1996; 110: 506-24.
225. Schäffer M, Witte M, Gottwald T, Köveker G, Becker HD. Stickstoffmonoxid: Mediator der Gewebsreparation? Dtsch Med Wochenschr 1997; 122: 339-45.
226. Jacob TD, Ochoa JB, Udekwu AO, Wilkinson J, Murray T, Billiar TR et at. Nitric oxide production is inhibited in trauma patients. J Trauma 1993; 35: 590-7.